Core Insights - Medtronic plc (NYSE:MDT) is recognized as one of the 13 Cheapest Dividend Aristocrats to invest in [1] Group 1: Analyst Upgrades and Market Potential - Needham & Company upgraded Medtronic from Hold to Buy, setting a price target of $121, citing early-phase product rollouts targeting multi-billion dollar markets that are expected to accelerate revenue growth [2] - The new products are projected to contribute over 1% to Medtronic's overall organic revenue growth, with expectations that Elliott Management's involvement will enhance execution, organic growth, and profitability [2] Group 2: Acquisition Strategy - Medtronic plans to acquire CathWorks for up to $585 million to expand its heart devices portfolio, which currently generates nearly 40% of its revenue [3] - The acquisition includes CathWorks' FFRangio System, a non-invasive diagnostic platform for coronary artery disease, further strengthening Medtronic's position in data-driven cardiac care [3] - The transaction is based on a partnership formed in 2022 and is subject to US regulatory approval, with an expected closing by the end of fiscal 2026 [4]